Compare FDUS & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDUS | MDXG |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 775.5M | 672.8M |
| IPO Year | 2011 | 2007 |
| Metric | FDUS | MDXG |
|---|---|---|
| Price | $19.44 | $3.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $21.60 | $7.00 |
| AVG Volume (30 Days) | 270.1K | ★ 1.8M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | ★ 11.28% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ 1.68 | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $17.63 | N/A |
| Revenue Next Year | $0.42 | $12.42 |
| P/E Ratio | $11.51 | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $16.87 | $3.03 |
| 52 Week High | $20.78 | $7.51 |
| Indicator | FDUS | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 25.43 |
| Support Level | $19.20 | $3.09 |
| Resistance Level | $19.81 | $3.84 |
| Average True Range (ATR) | 0.33 | 0.22 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 53.13 | 13.47 |
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.